Recent advancements in tuberculosis (TB) treatment are reshaping how the disease is understood and managed, particu- larly through improved differentiation between TB infection and active disease, which enables more tailored treatment approaches. Rifapentine-based regimens are at the forefront, offering shorter treatment durations and better patient adher- ence, making them especially valuable for individuals living with HIV or managing multiple comorbidities. While these advancements offer great potential, the letter stresses the ongoing challenges faced by marginalized populations, includ- ing delayed diagnosis and poor access to quality care, which hinder global TB control efforts. It calls for availability of rifapentine in Europe to ensure equitable treatment access and support the WHO’s TB eradication goals.
Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees
Giacomo Guido;Francesco Di Gennaro;
2025-01-01
Abstract
Recent advancements in tuberculosis (TB) treatment are reshaping how the disease is understood and managed, particu- larly through improved differentiation between TB infection and active disease, which enables more tailored treatment approaches. Rifapentine-based regimens are at the forefront, offering shorter treatment durations and better patient adher- ence, making them especially valuable for individuals living with HIV or managing multiple comorbidities. While these advancements offer great potential, the letter stresses the ongoing challenges faced by marginalized populations, includ- ing delayed diagnosis and poor access to quality care, which hinder global TB control efforts. It calls for availability of rifapentine in Europe to ensure equitable treatment access and support the WHO’s TB eradication goals.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
